Nanotechnology-based drug delivery offers new treatment options for deadly pancreatic cancers


November 30, 2009

Technology Review

Nanoparticles that deliver two or more drugs simultaneously can significantly shrink pancreatic cancer tumors and also reduce its spread, say researchers at Massachusetts General Hospital. Tayyaba Hasan, who is also a professor of dermatology at Harvard Medical School, led the development and testing of two "nanocells." These nanocells combine light-based therapy with molecules that inhibit the growth of cancer cells or of the blood vessels that feed them.

Though the particles have only been studied in mice so far, the cancer-research community is excited. Pancreatic cancer remains one of the deadliest and hardest cancers to treat; mortality rates have changed very little in the last 30 years. After diagnosis, patients tend to live only six months, and less than 5 percent survive for five years. "In terms of a patient population, there is very little we can do for them once we find the cancer," says Craig Thompson, director of the Abramson Cancer Center at the University of Pennsylvania... Read More